WO2005077917A1 - Sels de magnesium amorphes de la rosuvastatine - Google Patents

Sels de magnesium amorphes de la rosuvastatine Download PDF

Info

Publication number
WO2005077917A1
WO2005077917A1 PCT/IB2005/000132 IB2005000132W WO2005077917A1 WO 2005077917 A1 WO2005077917 A1 WO 2005077917A1 IB 2005000132 W IB2005000132 W IB 2005000132W WO 2005077917 A1 WO2005077917 A1 WO 2005077917A1
Authority
WO
WIPO (PCT)
Prior art keywords
rosuvastatin
magnesium
amorphous
crystalline
rosuvastatin magnesium
Prior art date
Application number
PCT/IB2005/000132
Other languages
English (en)
Inventor
Yatendra Kumar
Mohammad Rafeeq
Shantanu De
Swargam Sathyanarayana
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Priority to EP05702294A priority Critical patent/EP1737828A1/fr
Publication of WO2005077917A1 publication Critical patent/WO2005077917A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom

Definitions

  • This invention relates to amorphous salts of HMG Co A reductase inhibitors, and in particular, amorphous rosuvastatin magnesium, and processes for preparation thereof from crystalline rosuvastatin magnesium, rosuvastatin methyl ammonium salt and from rosuvastatin lactone.
  • Rosuvastatin magnesium is, chemically, (3R,5S,6E)-7-[4-(4-fluorophenyl)-6-(l- methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-6-heptenoic acid, magnesium salt (2: 1) of Formula I.
  • Rosuvastatin magnesium is an antihypercholesterolemic drug used in the treatment of atherosclerosis.
  • the difference in the activity of different polymorphic forms of a given drug has drawn the attention of many workers in recent years to undertake the studies on polymorphism. This has especially become very interesting since many antibiotics, antibacterials, tranquilizers exhibit polymorphism and particular polymorphic forms of a given drug can exhibit superior bioavailability and consequently show much higher activity compared to other forms.
  • polymorphism includes different physical forms, crystal forms, and crystalline / liquid crystalline / non-crystalline (amorphous) forms.
  • US Patent No. 6,589,959 describes a process for preparation of crystalline form A of rosuvastatin by warming the amorphous form of rosuvastatin calcium in a mixture of water and acetonitrile, cooling the resultant solution to ambient temperature and then filtering the product which is then dried at 50°C under vacuum to give crystalline Form A of rosuvastatin calcium.
  • the preparation of crystalline rosuvastatin magnesium salt is described in PCT patent application WO 01/60804 from rosuvastatin methyl ammonium salt of Formula II.
  • Rosuvastatin methyl ammonium salt is treated with sodium hydroxide in water to get free rosuvastatin acid, which is then reacted, with magnesium sulphate to get rosuvastatin magnesium salt, which is then isolated and dried.
  • the dried magnesium salt is then heated with water and after diluting the reaction mass with water; the resultant solution is then allowed to stand for 66 hours followed by filtration of the crystalline magnesium salt.
  • Amorphous rosuvastatin salts can be more effective pharmaceutically than the corresponding crystalline forms.
  • Amorphous forms can be very difficult to isolate and can pose problems with respect to purity and impurity profile.
  • Amorphous forms can also have stability issued and can convert to more stable crystalline forms by absorption of moisture from atmosphere.
  • the present inventors have set out to prepare heretofore unknown amorphous rosuvastatin magnesium having a high purity.
  • stable amorphous rosuvastatin magnesium is provided.
  • amorphous rosuvastatin magnesium when made by the processes of the present invention is easy to isolate and handle, thus making the process amenable for commercial scale use.
  • the purity of the amorphous rosuvastatin magnesium of the present invention is greater than 99%, with diastereomeric impurity less than 0.5%.
  • Figure 1 is an X-ray powder diffraction (XRD) pattern of amorphous rosuvastatin magnesium.
  • Figure 2 is an X-ray powder diffraction (XRD) pattern of crystalline rosuvastatin magnesium.
  • Figure 3 is an X-ray powder diffraction (XRD) ⁇ pattern of a mixture of largely amorphous mixed with some crystalline rosuvastatin magnesium.
  • Figure 4 is an X-ray powder diffraction (XRD) pattern of amorphous rosuvastatin calcium.
  • Figure 5 is an X-ray powder diffraction (XRD) pattern of crystalline rosuvastatin calcium.
  • amorphous rosuvastatin magnesium of Formula I is provided.
  • the purity of the amorphous form is greater than 99%, with diastereomeric impurity less than 0.5%).
  • the purity is greater than 99.5%, with diastereomeric impurity less than 0.25%, or for example the purity is greater than 99.8%, with diastereomeric impurity less than 0.15%.
  • Amorphous rosuvastatin magnesium substantially free of crystalline rosuvastatin magnesium is also provided herein.
  • an improved process for the preparation of crystalline rosuvastatin magnesium from rosuvastatin methyl ammonium salt or from rosuvastatin lactone comprises a) treating rosuvastatin methyl ammonium salt or rosuvastatin lactone with a base and magnesium salt. b) isolating crystalline rosuvastatin magnesium from the reaction mass. Rosuvastatin methyl ammonium salt of Formula II
  • FORMULA II can be prepared by the process described in PCT application WO 01/60804. Rosuvastatin methyl ammonium salt can be treated with a base in presence of water optionally containing an organic solvent. The reaction mass can then be partially concentrated to remove excess methylamine or ammonia liberated. The reaction mass can then be treated with a compound capable of generating magnesium ions, at a temperature of about 20 to 45°C under stirring. The solution can then finally be cooled to room temperature and filtered to get crystalline rosuvastatin magnesium. The entire process can be carried out in- situ without isolating any other salt of rosuvastatin, such as sodium or calcium.
  • the product obtained can further be crystallized from water, which generally involves 4 hours of stirring, and about 66 hours of standing, followed by filtration.
  • the process of present invention is less time-consuming and simple to operate on a commercial scale.
  • FORMULA III is treated with a base in the presence of water optionally containing an organic solvent, at a temperature of about 20 to 45°C till hydrolysis of lactone is completed.
  • the organic solvent can be then completely or partially removed.
  • the resultant reaction mass can then be treated with a compound capable of generating magnesium ions at a temperature of about 20 to 45°C under stirring.
  • the solution can then finally be cooled to room temperature and filtered to get crystalline rosuvastatin magnesium.
  • the entire process can be carried out in-situ without isolating any other salt of rosuvastatin, such as sodium or calcium.
  • the crystalline rosuvastatin magnesium obtained can have a purity above about 99% with diastereomeric impurities less than about 0.5%, for example purity above 99.25% with diastereomeric impurities less than 0.25%.
  • the crystalline material can be used as such for the purpose of preparing medicament and also for the preparation of amorphous rosuvastatin magnesium or amorphous rosuvastatin calcium.
  • the base is selected from, for example, sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium hydroxide, potassium carbonate or potassium bicarbonate.
  • the magnesium ions can be generated by using a magnesium compound selected from, for example, magnesium chloride, magnesium hydroxide, magnesium carbonate, magnesium acetate, magnesium sulphate, magnesium borate, magnesium tartarate, magnesium bromide or any other compound capable of generating magnesium ions.
  • the organic solvent can comprise lower alkanols, ethers, esters, ketones, polar aprotic solvents, alkyl or cycloalkyl hydrocarbons or mixtures thereof.
  • the lower alkanol can be, for example, methanol, ethanol, isopropanol, isobutanol, n-butanol and n-propanol.
  • the ethers can be, for example, tetrahydrofuran, 1,4-dioxane, diethyl ether and diisopropyl ether.
  • the esters can be, for example, ethyl formate, methyl acetate, ethyl acetate, isopropyl acetate, n-propyl acetate, isobutyl acetate, butyl acetate and a yl acetate.
  • the ketones can be, for example, acetone, ethyl methyl ketone, methyl isobutyl ketone and diisobutyl ketone.
  • Polar aprotic solvents can be, for example, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulphoxide, acetonitrile and N-methylpyrrolidone.
  • Alkyl or cycloalkyl hydrocarbons can be, for example, cyclop entane, cyclohexane, cycloheptane, hexane, petroleum ether, heptane or mixtures thereof.
  • a process for preparation of crystalline rosuvastatin magnesium from rosuvastatin methyl ammonium salt of Formula II is provided.
  • the process comprises a) lactonizing the rosuvastatin methyl ammonium salt of Formula II to give rosuvastatin lactone of Formula III; b) optionally isolating the rosuvastatin lactone of Formula III; c) converting the rosuvastatin lactone to the rosuvastatin magnesium by treatment with a base and a magnesium salt; and d) recovering the crystalline rosuvastatin magnesium from the reaction mass.
  • FORMULA II can be prepared by the process described in PCT application WO 01/60804. Rosuvasatin methyl ammonium salt can be treated with an acid (pH of about 1 to 5) to get rosuvastatin lactone of Formula III
  • the reaction can be carried out in presence of a first organic solvent, optionally containing water, at a temperature of about -10 to 100°C. After completion of the reaction, the layers are separated and organic layer after washing with water and/or brine can be concentrated under vacuum. The residue can be taken up in a second organic solvent. The mixture can be stirred at a temperature of about 40 to about 150°C for about 1 to 50 hours to affect lactonization. After completion of lactonization, the second organic solvent can be removed from the reaction mass under vacuum and the residue can be treated with third organic solvent to get the rosuvastatin lactone. The residue can be taken directly to the next step without actually isolating the lactone.
  • a first organic solvent optionally containing water
  • the acid can be, for example, an inorganic mineral acid such as hydrochloric acid, sulfuric acid, nitric acid, or phosphoric acid, or an organic acid such as formic acid, acetic acid and the like.
  • the first organic solvent can be, for example, water immiscible or partially miscible organic solvent such as, for example, toluene, xylene, benzene, ethyl methyl ketone, diisobutyl ketone, methyl isobutyl ketone, methyl t-butyl ether, diisopropyl ether, ethyl acetate, methyl formate, methyl acetate, isobutyl acetate, n-propyl acetate, isopropyl acetate, amyl acetate or mixtures thereof.
  • the second organic solvent can be, for example, methyl t-butyl ether, toluene, xylene, benzene, diisopropyl ether, n-butanol, isobutyl acetate, ethyl methyl ketone, diisobutyl ketone or mixtures thereof.
  • the third organic solvent in which rosuvastatin is insoluble or very slightly soluble or sparingly soluble can be, for example, isopropanol, isobutanol, n-butanol, cyclopentane, cyclohexane, cycloheptane, hexane, petroleum ether, heptane, diethyl ether, diisopropyl ether or mixtures thereof.
  • insoluble, very slightly soluble or sparingly soluble is mentioned, it is in accordance with the description provided in the United States Pharmacopoeia 2002.
  • a process for preparing amorphous rosuvastatin magnesium from crystalline form comprises a) dissolving the crystalline form in a suitable organic solvent; b) removing solvent from the said solution; and c) recovering amorphous rosuvastatin magnesium.
  • Crystalline rosuvastatin magnesium can be prepared by methods described above.
  • the crystalline form can be dissolved in an organic solvent.
  • the solvent can then be removed from the solution to get amorphous rosuvastatin magnesium.
  • the amorphous rosuvastatin magnesium thus obtained can be dried using conventional drying techniques such as vacuum tray drying, rotary vacuum drying, fluidized bed drier, tray drying and the like.
  • the organic solvent can be, for example, lower alkanols, ethers, esters, ketones, polar aprotic solvents or mixtures thereof.
  • the lower alkanol can be, for example, methanol, ethanol, isopropanol and n-propanol.
  • the ethers can be, for example, tetrahydrofuran and 1,4-dioxane.
  • the esters can be, for example, ethyl formate, methyl acetate, ethyl acetate, isopropyl acetate, n-propyl acetate, isobutyl acetate, butyl acetate and amyl acetate.
  • the ketones can be, for example, acetone, ethyl methyl ketone, methyl isobutyl ketone and diisobutyl ketone.
  • Polar aprotic solvents can be, for example, N,N- dimethylformamide, N,N-dimethylacetamide, dimethylsulphoxide, acetonitrile and N- methylpyrrolidone.
  • the solution of crystalline rosuvastatin magnesium can be prepared in the organic solvent by optional warming to dissolve the solids. If required, the solution can be clarified to remove the undissolved foreign particulate matter. The solution can then be concentrated to remove solvent. The concentration can be carried out under vacuum of about 100 to about 0.01 mm of Hg wherein the solvent is removed by vacuum distillation while optionally heating the solution at a temperature of about 15 to about 55°C to effect faster removal of the solvent.
  • the solvent can also be removed by spray-drying the solution of crystalline rosuvastatin calcium using a spray-dryer. For the purpose of spray-drying, mini-spray Dryer (Model: Buchi 190 Switzerland) which operates on the principle of nozzle spraying in a parallel - flow i.e.
  • the drying gas can be air or inert gases such as nitrogen, argon or carbon dioxide.
  • a process for preparing amorphous rosuvastatin magnesium from crystalline form is provided.
  • the process comprises a) dissolving the crystalline form of rosuvastatin magnesium in a suitable first organic solvent; b) adding a second organic solvent to the solution of rosuvastatin magnesium or adding the solution of rosuvastatin magnesium to the second organic solvent (in optional order of succession) in which rosuvastatin magnesium is insoluble or very slightly soluble or sparingly soluble, such that amorphous rosuvastatin magnesium precipitates out from the solution; and c) isolating the amorphous rosuvastatin magnesium from the mixture.
  • Crystalline rosuvastatin magnesium can be dissolved in a first organic solvent and to the solution added a second solvent or added solution of rosuvastatin magnesium to the second organic solvent (in optional order of succession) in which rosuvastatin is insoluble or very slightly soluble or sparingly soluble. Due to addition of the second solvent, rosuvastatin magnesium precipitates out from the solution. The precipitated product can then be isolated and dried by conventional techniques to get the amorphous rosuvastatin magnesium.
  • the suitable first organic solvent can be for example lower alkanols, ethers, esters, ketones, polar aprotic solvents or mixtures thereof.
  • the lower alkanol can be, for example, methanol, ethanol, isopropanol and n-propanol.
  • the ethers can be, for example, tetrahydrofuran and 1,4-dioxane.
  • the esters can be, for example, ethyl formate, methyl acetate, ethyl acetate, isopropyl acetate, n-propyl acetate, isobutyl acetate, butyl acetate and amyl acetate.
  • the ketones can be, for example, acetone, ethyl methyl ketone, methyl isobutyl ketone and diisobutyl ketone.
  • Polar aprotic solvents can be, for example, N,N- dimethylformamide, N,N-dimethylacetamide, dimethylsulphoxide, acetonitrile and N- methylpyrrolidone.
  • the second organic solvent in which rosuvastatin is insoluble (10,000 and over parts of solvent required for 1 part of solute as per United States Pharmacopoeia 2002) or very slightly soluble (form 1,000 to 10,000 parts of solvent required for 1 part of solute as per United States Pharmacopoeia 2002) or sparingly soluble (from 30 to 100 parts of solvent required for 1 part of solute as per United States Pharmacopoeia 2002) can be, for example, isopropanol, isobutanol, n-butanol, cyclopentane, cyclohexane, cycloheptane, hexane, petroleum ether, heptane, diethyl ether, diisopropyl ether or mixtures thereof.
  • a process for preparation of amorphous rosuvastatin magnesium from crystalline rosuvastatin magnesium comprises a) dissolving the crystalline rosuvastatin magnesium in a suitable organic solvent; b) adding water to the solution of rosuvastatin magnesium, or adding the solution of rosuvastatin magnesium to water (in optional order of succession), such that rosuvastatin magnesium precipitates out from the solution; and c) isolating the amorphous rosuvastatin magnesium from the mixture.
  • Crystalline rosuvastatin magnesium can be dissolved in an organic solvent and the solution can be optionally treated with charcoal or clarified to remove foreign particulate matter.
  • the clear solution can be obtained by gently warming the mixture as well.
  • water can be added at such a rate that rosuvastatin magnesium precipitates slowly.
  • the mixture after complete addition of water can be chilled or partially concentrated to remove the organic solvent.
  • the separated amorphous form can then be filtered and dried as per the methods described earlier.
  • the suitable organic solvent can be, for example, methanol, ethanol, isopropanol, n-propanol, tetrahydrofuran, 1,4-dioxane, acetone, N,N-dimethylformamide, N,N- dimethylacetamide, dimethylsulphoxide, acetonitrile and N-methylpyrrolidone or mixtures thereof.
  • a process for preparing amorphous rosuvastatin magnesium from crystalline form comprises:, a) subjecting crystalline rosuvastatin magnesium to milling until the crystalline form is converted to amorphous form; and b) optionally drying the amorphous form.
  • Crystalline rosuvastatin magnesium solid or its slurry in an organic solvent can be milled by grinding between two surfaces. Such milling can be carried out by using a traditional technique of compounding using a pestle and mortar or by milling machines that essentially use the same principle. Examples of such milling machines include various makes of ball mills, roller mills, gyratory mills, and the like.
  • the slurry of crystalline rosuvastatin magnesium in an organic solvent can be of 30 to 85% w/v.
  • the organic solvent in which rosuvastatin is insoluble or very slightly soluble or sparingly soluble can be, for example, isopropanol, isobutanol, n-butanol, cyclopentane, cyclohexane, cycloheptane, hexane, petroleum ether, heptane, diethyl ether, diisopropyl ether or mixtures thereof.
  • a process for preparing amorphous rosuvastatin magnesium from crystalline form comprises: a) dissolving crystalline rosuvastatin magnesium in an organic solvent optionally containing water; and b) freeze drying or lyophilizing the solution to get amorphous rosuvastatin magnesium.
  • a solution of crystalline rosuvastatin magnesium in an organic solvent optionally containing water can be prepared and treated with charcoal, filtered to remove charcoal.
  • the clear solution is then freeze-dried by conventional techniques to get the amorphous rosuvastatin magnesium.
  • the amorphous form can then be dried under vacuum.
  • the organic solvent can be, for example, lower alkanols, ethers, esters, ketones, polar aprotic solvents or mixtures thereof.
  • the lower alkanol can be, for example, methanol, ethanol, isopropanol and n-propanol.
  • the ethers are selected from tetrahydrofuran and 1,4-dioxane.
  • the esters can be, for example, ethyl formate, methyl acetate, ethyl acetate, isopropyl acetate, n-propyl acetate, isobutyl acetate, butyl acetate and amyl acetate.
  • the ketones can be, for example, acetone, ethyl methyl ketone, methyl isobutyl ketone and diisobutyl ketone.
  • Polar aprotic solvents can be, for example, N,N- dimethylformamide, N,N-dimethylacetamide, dimethylsulphoxide, acetonitrile and N- methylpyrrolidone.
  • a process for preparation of amorphous rosuvastatin magnesium from rosuvastatin methyl ammonium salt of Formula II comprises:
  • Rosuvastatin methyl ammonium salt can be converted to rosuvastatin magnesium as described above.
  • a suitable organic solvent capable or azeotropically removing water and simultaneously capable of dissolving rosuvastatin magnesium. From the resulting mixture, water was removed and from the solution of rosuvastatin magnesium, solvent was removed to get the desired amorphous rosuvastatin magnesium as solid.
  • an organic solvent which dissolves rosuvastatin magnesium and is immiscible or partially miscible with water.
  • the solvent can be made immiscible in water by increasing the salinity of the aqueous layer, using for example,sodium chloride or calcium chloride.
  • the layers can be separated and the organic layer containing rosuvastatin magnesium can then be dried, for example, over magnesium sulphate, sodium sulphate or molecular sieves to remove traces of water.
  • the organic layer can then be concentrated to remove solvent, and get the desired amorphous rosuvastatin magnesium.
  • the concentration can be effected by either spray drying or by vacuum distillation.
  • the organic solvent can be, for example, tetrahydrofuran, 1,4-dioxane, toluene, xylene, dichloromethane, ethyl formate, methyl acetate, ethyl acetate, isopropyl acetate, n- propyl acetate, isobutyl acetate, butyl acetate, amyl acetate, ethyl methyl ketone, methyl isobutyl ketone and diisobutyl ketone or mixtures thereof.
  • a process of preparation of amorphous rosuvastatin magnesium from crystalline form comprises: a) treating crystalline rosuvastatin magnesium with an acid to obtain rosuvastatin; b) optionally isolating rosuvastatin; c) converting rosuvastatin to rosuvastatin magnesium by treatment with a base and magnesium salt; d) removing water from the reaction mass by azeotropic distillation using an organic solvent; and e) recovering the amorphous form of rosuvastatin magnesium by removing the organic solvent from the resultant solution.
  • Crystalline rosuvastatin magnesium can be treated with an acid to get rosuvastatin acid.
  • the conversion can be easily carried out in presence of water optionally containing an organic solvent.
  • the reaction temperature can be kept at about -5 to 100°C for example.
  • the organic solvent can be, for example, lower alkanols, ethers, esters, ketones, polar aprotic solvents, alkyl or cycloalkyl hydrocarbons or mixtures thereof.
  • the lower alkanol can be, for example, methanol, ethanol, isopropanol, isobutanol, n-butanol and n- propanol.
  • the ethers can be, for example, tetrahydrofuran, 1,4-dioxane, diethyl ether and diisopropyl ether.
  • the esters can be, for example, ethyl formate, methyl acetate, ethyl acetate, isopropyl acetate, n-propyl acetate, isobutyl acetate, butyl acetate and amyl acetate.
  • the ketones can be, for example, acetone, ethyl methyl ketone, methyl isobutyl ketone and diisobutyl ketone.
  • Polar aprotic solvents can be, for example, N,N- dimethylformamide, N,N-dimethylacetamide, dimethylsulphoxide, acetonitrile and N- methylpyrrolidone.
  • Alkyl or cycloalkyl hydrocarbons can be, for example, cyclopentane, cyclohexane, cycloheptane, hexane, petroleum ether, heptane or mixtures thereof.
  • the aqueous layer can be extracted with organic solvent, as described above.
  • the organic layer after evaporation of solvent under vacuum gives rosuvastatin acid as oily residue.
  • the residue can be dissolved in water and organic solvent and treated with a base and magnesium ions to get rosuvastatin magnesium.
  • To the reaction mass can be added a suitable second organic solvent capable of azeotropically removing water and simultaneously capable of dissolving rosuvastatin magnesium. From the resulting mixture water was removed and from the solution of rosuvastatin magnesium, solvent was removed to get the desired amorphous rosuvastatin magnesium as solid.
  • a second organic solvent which dissolves rosuvastatin magnesium and is immiscible or partially miscible with water.
  • the solvent can be made immiscible in water by increasing the salinity of the aqueous layer using, for example, sodium chloride or calcium chloride.
  • the layers are separated and the organic layer containing rosuvastatin magnesium is then dried over magnesium sulphate, sodium sulphate or molecular sieves to remove traces of water.
  • the organic layer can then be concentrated to remove solvent to get the desired amorphous rosuvastatin magnesium.
  • the concentration can be effected by either spray-drying or by vacuum distillation.
  • the second organic solvent can be, for example, tetrahydrofuran, 1,4-dioxane, toluene, xylene, dichloromefhane, ethyl formate, methyl acetate, ethyl acetate, isopropyl acetate, n-propyl acetate, isobutyl acetate, butyl acetate, amyl acetate, ethyl methyl ketone, methyl isobutyl ketone and diisobutyl ketone or mixtures thereof.
  • the acid used can be, for example, inorganic acid such as hydrochloric acid, sulphuric acid, phosphoric acid, hydrobromic acid, nitric acid and the like or a mixture thereof; or an organic acid, such as formic acid, acetic acid, propionic acid, anhydrides of carboxylic acids, methanesulphonic acid, 4-toluenesulphonic acid and the like.
  • inorganic acid such as hydrochloric acid, sulphuric acid, phosphoric acid, hydrobromic acid, nitric acid and the like or a mixture thereof
  • organic acid such as formic acid, acetic acid, propionic acid, anhydrides of carboxylic acids, methanesulphonic acid, 4-toluenesulphonic acid and the like.
  • a process for preparation of amorphous rosuvastatin magnesium from rosuvastatin methyl ammonium salt of Formula II comprises:
  • Rosuvastatin methyl ammonium salt can be converted to rosuvastatin magnesium as described above. However, after treating the aqueous layer with magnesium ions, to the reaction mass can be added a suitable organic solvent capable of azeotropically removing water and simultaneously capable of dissolving rosuvastatin magnesium. From the resulting mixture water can be removed and from the solution of rosuvastatin calcium, solvent can be removed to get the desired amorphous rosuvastatin magnesium as solid.
  • an organic solvent which dissolves rosuvastatin magnesium and is immiscible or partially miscible with water.
  • the solvent can be made immiscible in water by increasing the salinity of the aqueous layer using, for example, sodium chloride or calcium chloride.
  • the layers are separated and the organic layer containing rosuvastatin calcium is then dried over calcium chloride, sodium sulphate or molecular sieves to remove traces of water.
  • the organic layer can then be concentrated to remove solvent to get the desired amorphous rosuvastatin magnesium.
  • the concentration can be effected by either spray- drying or by vacuum distillation.
  • the organic solvent can be, for example, tetrahydrofuran, 1,4-dioxane, toluene, xylene, dichloromethane, ethyl formate, methyl acetate, ethyl acetate, isopropyl acetate, n- propyl acetate, isobutyl acetate, butyl acetate, amyl acetate, ethyl methyl ketone, methyl isobutyl ketone and diisobutyl ketone or mixtures thereof.
  • a process for converting a mixture of amorphous and crystalline form of rosuvastatin magnesium to completely amorphous rosuvastatin magnesium is provided.
  • a mixture of largely amorphous with some crystalline rosuvastatin magnesium can be prepared directly from the rosuvastatin lactone or rosuvastatin methyl ammonium salt or from the crystalline form by the process already described in the specification with little variations.
  • the crystalline rosuvastatin magnesium can be converted to a mixture of amorphous and crystalline material by techniques described above.
  • the mixture of largely amorphous rosuvastatin magnesium containing some crystalline form can then be converted to the amorphous form by techniques described Above.
  • the use of amorphous rosuvastatin magnesium in the preparation of rosuvastatin calcium either in crystalline or in amorphous form is provided.
  • the aspect further provides a process for preparation of rosuvastatin calcium from amorphous rosuvastatin magnesium.
  • the process comprises a) reating amorphous rosuvastatin magnesium with a base and a calcium salt; and b) isolating rosuvastatin calcium from the reaction mass.
  • the amorphous rosuvastatin magnesium can be treated with a base in presence of water optionally containing an organic solvent.
  • the resultant mass can be concentrated partially to remove the organic solvent, followed by addition of the solution of calcium salt in water under vigorous stirring at such a rate that amorphous rosuvastatin calcium separates out from the reaction mass slowly. After complete addition the mass can be further stirred at temperature of about 10 to 30°C for about 1 to about 10 hours and filtered to get amorphous rosuvastatin calcium, which can be dried, for example, under vacuum.
  • amorphous rosuvastatin calcium can then be crystallized by methods described in, for example, US Patent No. 6,589,959 to get crystalline rosuvastatin calcium which can be further converted to amorphous rosuvastatin calcium by methods described in, for example, co-pending Indian application 1304/DEL/2003.
  • amorphous rosuvastatin magnesium having an X-ray diffraction pattern as depicted in Figure I is provided.
  • compositions and dosage fo ⁇ ns comprising the amorphous rosuvastatin magnesium to be used as HMG-CoA reductase inhibitor in treatment of hyperlipidemia are provided.
  • a method inhibiting HMG-CoA enzyme in treatment of hyperlipidemia comprising administering to a mammal in need thereof a therapeutically effective amount of the amorphous rosuvastatin magnesium is provided.
  • Example 1 Preparation of Crystalline Rosuvastatin Magnesium from Rosuvastatin Methyl Ammonium Salt
  • Rosuvastatin methyl ammonium salt of Formula II (10 g) was added into water (50 ml) and to the resultant mass added a solution of aqueous sodium hydroxide (9 ml, 8% w/v) at 25-30oC and stirred for further 30 min.
  • the solution was filtered through celite bed and the bed was washed with water (20 ml).
  • the reaction mass concentrated to recover water (40 ml) under vacuum at 60°C.
  • To the reaction mass was added water (40 ml) and the equivalent quantity of water was removed under vacuum.
  • the final solution was diluted with water (50 ml).
  • Diastereomeric impurity 0.27%
  • Rosuvastatin lactone of Formula III (5.0 g) was suspended in methanol (50 ml) and water (25 ml) at 25-30°C. To this mixture was added solution of aqueous sodium hydroxide (4.5 ml, 8% w/v) at 25-30°C and then further stirred at 35°C for 1 hour. After complete hydrolysis of lactone, methanol was recovered under reduced pressure at temperature below 45°C. To this solution was added water (15 ml) and a solution of magnesium diacetate tetrahydrate (1.34 g) in water (5 ml) at 35°C under vigorous agitation. The reaction mass was further stirred for 1 hour at 35°C and then cooled to 25- 30°C. After complete precipitation of magnesium salt, it was filtered and the cake was washed with water (15 ml). The product was dried at 45 to 50°C.
  • aqueous sodium hydroxide 4.5 ml, 8% w/v
  • Rosuvastatin methyl ammonium salt (20 gm) was added into mixture of ethyl acetate (100 ml) and water (200 ml) at 25-30°C and the pH of the reaction mass was adjusted to about 3.0 with 6N hydrochloric acid. The layers were separated and the organic layer is washed with water (50 ml). The organic layer was concentrated under vacuum to get an oily crude product, which was mixed with toluene (50 ml). The reaction mass was refluxed for about 6 hours and the solvent was removed under vacuum at 60°C. The residue obtained was stirred with hexane (100 ml) and the separated solid was filtered. Dried the product under vacuum till constant weight at 40-45°C to get rosuvastatin lactone.
  • Rosuvastatin lactone of Formula III (5.0 g) was suspended in methanol (50 ml) and water (25 ml) at 25-30°C. To this mixture was added solution of aqueous sodium hydroxide (4.5 ml, 8% w/v) at 25-30°C and then further stirred at 35°C for 1 hour. After complete hydrolysis of lactone, methanol was recovered under reduced pressure at temperature below 45°C. To this solution was added water (15 ml) and a solution of magnesium diacetate tetrahydrate (1.34 g) in water (5 ml) at 35°C under vigorous agitation. The reaction mass was further stirred for 1 hour at 35°C and then cooled to 25- 30°C. After complete precipitation of magnesium salt, it was filtered and the cake was washed with water (15 ml). The product was dried at 45 to 50°C.
  • aqueous sodium hydroxide 4.5 ml, 8% w/v
  • Diastereomeric impurity 0.34%
  • Crystalline rosuvastatin magnesium (2.0 gm) was slurried in cyclohexane (10 ml) and the slurry was placed in a glass mortar. The slurry was triturated with pestle till the crystalline form was completely converted to amorphous form. The slurry was then filtered and the solid was dried under vacuum at 40-45°C to get amorphous rosuvastatin magnesium.
  • Example 8 Preparation of Rosuvastatin Magnesium Amorphous grom Crystalline Rosuvastatin Magnesium By Freeze Drying Crystalline rosuvastatin magnesium (1.0 g) was dissolved in 1 ,4 dioxane (5 ml) by gently warming at 38°C. The solution was placed in a bath containing acetone and dry ice maintained at about -20 to -30°C and cooled to -20°C under rotation. The material was solidified by cooling and then vacuum of less than 0.1 mm of Hg was applied. The temperature of the bath was slowly raised from -20 to 10°C over 2 hours while under vacuum. Further temperature was raised to 10 to 25°C over 1 hour. Title compound was obtained was dried under vacuum at 45°C.
  • Rosuvastatin methyl ammonium salt (20 gm) was added into a mixture of ethyl acetate (100 ml) and water (200 ml) at 25-30°C and the pH of the reaction mass was adjusted to about 3.0 with 6N hydrochloric acid. The layers were separated and the organic layer washed with water (50 ml). The organic layer was concentrated under vacuum to get an crude oily product, which was mixed with toluene (50 ml). The reaction mass was refluxed for about 6 hours and the solvent was removed under vacuum at 60°C. The residue obtained was stirred with hexane (100 ml) and the separated solid was filtered. Dried the product under vacuum to constant weight at 40-45°C to get rosuvastatin lactone.
  • Step B) Preparation of Amorphous Rosuvastatin Magnesium from Rosuvastatin Lactone Rosuvastatin lactone of Fo ⁇ nula III (5.0 g) was suspended in methanol (50 ml) and water (25 ml) at 25-30°C. To this mixture was added solution of aqueous sodium hydroxide (4.5 ml, 8% w/v) at 25-30°C and then further stirred at 35°C for 1 hour. After complete hydrolysis of lactone, methanol was recovered under reduced pressure at temperature below 45°C.
  • aqueous sodium hydroxide 4.5 ml, 8% w/v
  • Crystalline rosuvastatin magnesium (10.0 g) was added into mixture of ethyl acetate (100 ml) and water (100 ml) at room temperature. The pH of the resulting solution was adjusted 4.0 to 4.2 by adding dilute hydrochloric acid at 25°C. The layers were separated and organic layer was washed with water. The solvent was concentrated under vacuum to get oily residue.
  • the oily residue obtained above was dissolved in methanol (35 ml) and water (50 ml) at room temperature.
  • the pH of the solution was adjusted with sodium hydroxide (8% solution in water) to about 8.5 to 9.0 and the resulting reaction mass was stirred for further 1 hour at room temperature. Methanol was removed under vacuum.
  • the oily residue was reconstituted in water (50 ml) and to the aqueous solution added a solution of magnesium diacetate tetrahydrate (2.8 g) in water (20 ml) at 20-22°C with vigorous stirring. Solid compound was precipitated out. Added to the slurry tetrahydrofuran (50 ml) and stirred for 10 minutes.
  • Rosuvastatin methyl ammonium salt of Formula II (10.0 g) was added into water (50 ml) and to it charged aqueous sodium hydroxide solution (9 ml, 8% w/v) at 25-30°C. The resultant mass was stirred for 20 minutes. The mass was filtered through celite bed and the bed was washed with water (20 ml). From the resultant clear solution water (40 ml) was recovered under vacuum at 60°C followed by addition of further water (40 ml). The mass was further concentrated to recover water (40 ml). After removal of water was added fresh water (40 ml) to the reaction mass.
  • Crystalline rosuvastatin magnesium (6.0 gm) was slurried in cyclohexane (10 ml) and the slurry was placed in a glass mortar. The slurry was triturated with pestle for about 25 to 30 hours. The slurry was then filtered and the solid was dried under vacuum at 40- 45°C to get the tile compound. Yield: 5.43 gm (90%) (XRD as per Figure 3 showed it to be a mixture of amorphous and crystalline material)
  • Step B Conversion of Mixture of Amorphous and Crystalline Rosuvastatin Magnesium to Amorphous Rosuvastatin Magnesium
  • the product obtained in step A) (2.0 g) was dissolved in tetrahydrofuran (5 ml) at
  • Amorphous rosuvastatin magnesium (10.0 g) was added into mixture of ethyl acetate (100 ml) and water (100 ml) at room temperature. The pH of the resulting solution was adjusted 4.0 to 4.2 by adding dilute hydrochloric acid at 25°C. The layers were separated and organic layer was washed with water. The solvent was concentrated under vacuum to get oily residue.
  • the oily residue obtained above was dissolved in methanol (35 ml) and water (50 ml) at room temperature.
  • the pH of the solution was adjusted with sodium hydroxide (8% w/v solution in water) to about 8.5 to 9.0 and the resulting reaction mass was stirred for further 1 hour at room temperature. Methanol was removed under vacuum.
  • the oily residue was reconstituted in water (50 ml) and to the aqueous solution added a solution of calcium acetate (2.1 gm) in water (10 ml) at 20-22oC with vigorous stirring. After complete addition, mixture was stirred for further 2 hours at 20-22oC and filtered, washed the cake with water (20 ml) thrice and then dried at 45oC under vacuum to get amorphous rosuvastatin calcium.
  • Example 13 The product obtained in Example 13 (5.0 gm) was added to a mixture of water (50 ml) and acetonitrile (50 ml) at 15oC. The mixture was warmed to 40oC to obtain complete solution. The mixture was then cooled slowly to 25-30oC and stirred for 16 hours. The crystalline product was separated by filtration at ambient temperature and dried at 50oC under vacuum to give rosuvastatin calcium as white crystals.

Abstract

L'invention porte sur le nouveau magnésium amorphe de la rosuvastatine et sur son procédé de préparation à partir du magnésium cristallin de la rosuvastatine, du sel de méthyl ammonium de la rosuvastatine et de la lactone de la rosuvastatine. Le magnésium de la rosuvastatine est, chimiquement, l'acide (3R, 5S,6E)-7-[4-(4-fluorophényl)-6-(1-méthyléthyl)-2-[méthyl(méthylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-6-heptonique, le sel de magnésium (2 :1) de formulée (I). Le magnésium de rosuvastatine est un médicament antihypercholestérolémique utilisé dans le traitement de l'athérosclérose.
PCT/IB2005/000132 2004-01-19 2005-01-19 Sels de magnesium amorphes de la rosuvastatine WO2005077917A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05702294A EP1737828A1 (fr) 2004-01-19 2005-01-19 Sels de magnesium amorphes de la rosuvastatine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN77DE2004 2004-01-19
IN77/DEL/2004 2004-01-19

Publications (1)

Publication Number Publication Date
WO2005077917A1 true WO2005077917A1 (fr) 2005-08-25

Family

ID=34856861

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/000132 WO2005077917A1 (fr) 2004-01-19 2005-01-19 Sels de magnesium amorphes de la rosuvastatine

Country Status (2)

Country Link
EP (1) EP1737828A1 (fr)
WO (1) WO2005077917A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006136407A1 (fr) * 2005-06-24 2006-12-28 Lek Pharmaceuticals D.D. Procede de preparation de rosuvastatine calcique amorphe depourvue d'impuretes
WO2006136408A3 (fr) * 2005-06-24 2007-04-19 Lek Pharmaceuticals Procédé de préparation de rosuvastatine calcique pure amorphe
WO2007071357A2 (fr) * 2005-12-20 2007-06-28 Lek Pharmaceuticals D.D. Composition pharmaceutique
US7511140B2 (en) 2002-08-13 2009-03-31 Astrazeneca Ab Process for preparing the calcium salt of rosuvastatin
WO2010128346A2 (fr) 2009-05-07 2010-11-11 Egis Gyógyszergyár Nyilvánosan Mukodo Reszvenytársaság Sels de rosuvastatine et leur procédé de préparation
US8063213B2 (en) 2003-06-05 2011-11-22 Astrazeneca Uk Limited Production of rosuvastatin calcium salt
WO2012066365A2 (fr) 2010-11-16 2012-05-24 EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság Ingrédients cristallins actifs au plan pharmaceutique
WO2012073256A1 (fr) 2010-11-29 2012-06-07 Cadila Healthcare Limited Sels de rosuvastatine
US9371291B2 (en) 2003-10-24 2016-06-21 Astrazeneca Uk Limited Process for the manufacture of the calcium salt of rosuvastatin (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]-pyrimidin-5-yl](3R,5S)-3,5-Dihydroxyhept-6-enoic acid and crystalline intermediates thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0521471A1 (fr) * 1991-07-01 1993-01-07 Shionogi Seiyaku Kabushiki Kaisha Dérivés de pyrimidine comme inhibiteurs de la HMG-CoA reductase
WO2001060804A1 (fr) * 2000-02-15 2001-08-23 Astrazeneca Ab Sels cristallises d'acide 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoique
WO2003016317A1 (fr) * 2001-08-16 2003-02-27 Teva Pharmaceutical Industries Ltd. Procedes permettant de preparer des formes salines calciques de statines
US6589959B1 (en) * 1999-01-09 2003-07-08 Astrazeneca Ab Crystalline bis[(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid]calcium salt
WO2004014872A1 (fr) * 2002-08-13 2004-02-19 Astrazeneca Uk Limited Procede de preparation de sel de calcium de rosuvastatine
WO2004108691A1 (fr) * 2003-06-05 2004-12-16 Astrazeneca Uk Limited Production amelioree du sel de calcium de rosuvastatine
WO2005021511A1 (fr) * 2003-08-27 2005-03-10 Hetero Drugs Limited Procede nouveau pour la rosuvastatine calcique amorphe

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0521471A1 (fr) * 1991-07-01 1993-01-07 Shionogi Seiyaku Kabushiki Kaisha Dérivés de pyrimidine comme inhibiteurs de la HMG-CoA reductase
US6589959B1 (en) * 1999-01-09 2003-07-08 Astrazeneca Ab Crystalline bis[(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid]calcium salt
WO2001060804A1 (fr) * 2000-02-15 2001-08-23 Astrazeneca Ab Sels cristallises d'acide 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoique
WO2003016317A1 (fr) * 2001-08-16 2003-02-27 Teva Pharmaceutical Industries Ltd. Procedes permettant de preparer des formes salines calciques de statines
WO2004014872A1 (fr) * 2002-08-13 2004-02-19 Astrazeneca Uk Limited Procede de preparation de sel de calcium de rosuvastatine
WO2004108691A1 (fr) * 2003-06-05 2004-12-16 Astrazeneca Uk Limited Production amelioree du sel de calcium de rosuvastatine
WO2005021511A1 (fr) * 2003-08-27 2005-03-10 Hetero Drugs Limited Procede nouveau pour la rosuvastatine calcique amorphe

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7511140B2 (en) 2002-08-13 2009-03-31 Astrazeneca Ab Process for preparing the calcium salt of rosuvastatin
US7842807B2 (en) 2002-08-13 2010-11-30 Astrazeneca Uk Limited Process for preparing the calcium salt of rosuvastatin
US8063213B2 (en) 2003-06-05 2011-11-22 Astrazeneca Uk Limited Production of rosuvastatin calcium salt
US9371291B2 (en) 2003-10-24 2016-06-21 Astrazeneca Uk Limited Process for the manufacture of the calcium salt of rosuvastatin (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]-pyrimidin-5-yl](3R,5S)-3,5-Dihydroxyhept-6-enoic acid and crystalline intermediates thereof
US8207333B2 (en) 2005-06-24 2012-06-26 Lek Pharmaceuticals D. D. Process for preparing pure amorphous rosuvastatin calcuim
AU2006261087B2 (en) * 2005-06-24 2010-09-30 Lek Pharmaceuticals D.D. Process for preparing amorphous rosuvastatin calcium free of impurities
WO2006136407A1 (fr) * 2005-06-24 2006-12-28 Lek Pharmaceuticals D.D. Procede de preparation de rosuvastatine calcique amorphe depourvue d'impuretes
US9150518B2 (en) 2005-06-24 2015-10-06 Lek Pharmaceuticals, D.D. Process for preparing amorphous rosuvastatin calcium of impurities
EP1915349B1 (fr) 2005-06-24 2015-12-09 LEK Pharmaceuticals d.d. Procédé de préparation de rosuvastatine calcique pure amorphe
WO2006136408A3 (fr) * 2005-06-24 2007-04-19 Lek Pharmaceuticals Procédé de préparation de rosuvastatine calcique pure amorphe
WO2007071357A3 (fr) * 2005-12-20 2007-11-08 Lek Pharmaceuticals Composition pharmaceutique
EA015682B1 (ru) * 2005-12-20 2011-10-31 Лек Фармасьютиклз Д.Д. Фармацевтическая композиция
WO2007071357A2 (fr) * 2005-12-20 2007-06-28 Lek Pharmaceuticals D.D. Composition pharmaceutique
WO2010128346A2 (fr) 2009-05-07 2010-11-11 Egis Gyógyszergyár Nyilvánosan Mukodo Reszvenytársaság Sels de rosuvastatine et leur procédé de préparation
WO2012066365A2 (fr) 2010-11-16 2012-05-24 EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság Ingrédients cristallins actifs au plan pharmaceutique
WO2012073256A1 (fr) 2010-11-29 2012-06-07 Cadila Healthcare Limited Sels de rosuvastatine

Also Published As

Publication number Publication date
EP1737828A1 (fr) 2007-01-03

Similar Documents

Publication Publication Date Title
US20070191318A1 (en) Process for the preparation of amorphous rosuvastatin calcium
EP1737828A1 (fr) Sels de magnesium amorphes de la rosuvastatine
WO2005077916A1 (fr) Sels des inhibiteurs de hmg-coa reductase et leur utilisation
ES2361009T3 (es) Procedimiento para preparar la sal de calcio de rosuvastatina.
JP2019142882A (ja) 結晶性ミノサイクリン塩基及びその製造方法
JP2008528542A5 (fr)
CN1388123A (zh) 氯代嘧啶中间体
JP2000514833A (ja) 結晶性セフジニルアミン塩
BRPI0410922B1 (pt) processo para a formação de um composto
EP2013188B1 (fr) Sel de zinc de rosuvastatine
WO2012066565A2 (fr) Maléate d'asénapine amorphe et forme cristalline et procédé pour leur préparation
WO2005121154A1 (fr) Procede de preparation de cefdinir
AU2007208965B2 (en) A process for manufacturing Rosuvastatin Potassium and crystalline and amorphous forms thereof
JP2013516459A (ja) ピタバスタチン及び医薬として許容可能なそれらの塩の製造方法
JP2013543884A (ja) 高純度の医薬品中間体の製法
US20100069635A1 (en) Rosuvastatin dehydroabietylamine salt
EP1689755A2 (fr) Procedes de preparation de cephalosporine de type 3-(2-substitue vinyle) de grande purete
JP3911124B2 (ja) セフポドキシムプロクセチルジアステレオ異性体の調製プロセス
WO2010091169A2 (fr) Préparation de valsartan
JPS5953277B2 (ja) 抗菌剤の製造方法
WO2005021511A1 (fr) Procede nouveau pour la rosuvastatine calcique amorphe
US20220259209A1 (en) Process for the preparation of abrocitinib
WO2021044350A1 (fr) Formes solides de mésylate d'encéquidar et procédés associés
WO2007092758A2 (fr) Formes cristallines de périndopril erbumine
US20060252789A1 (en) Amorphous moxifloxacin hydrochloride

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005702294

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 4805/DELNP/2006

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2005702294

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2005702294

Country of ref document: EP